Expand RVPH Menu
RVPH MENU

RVPH Latest Press Releases

-- March 23, 2026 --

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering Globe Newswire 8:00 AM

-- March 18, 2026 --

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering Globe Newswire 10:34 PM
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering Globe Newswire 4:10 PM

-- January 8, 2026 --

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia Globe Newswire 8:00 AM

-- December 29, 2025 --

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum Globe Newswire 8:00 AM

-- December 23, 2025 --

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia Globe Newswire 8:00 AM

-- November 13, 2025 --

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights Globe Newswire 4:05 PM

-- November 12, 2025 --

Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 Globe Newswire 8:00 AM

-- November 10, 2025 --

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis Globe Newswire 8:00 AM

-- October 29, 2025 --

Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference Globe Newswire 8:00 AM

-- October 28, 2025 --

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025 Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes